Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2018-01-05 AGM Information
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Zwołanie Nadzwyczajnego Walnego Zgromadzenia GLG Pharma S.A. na dzień 1 lutego 2018 r. - Content (PL)
AGM Information Classification · 98% confidence The document text explicitly states that the Management Board ('Zarząd') of GLG Pharma S.A. is convening an Extraordinary General Meeting ('Nadzwyczajne Walne Zgromadzenie Spółki' or 'NWZ') on February 1, 2018, and that the full text of the notice convening the NWZ along with draft resolutions is attached. This content directly relates to the formal process and materials surrounding a shareholder meeting, specifically the announcement of the meeting itself and associated documents. This aligns best with the 'AGM Information' category, which covers presentations and materials shared during General Meetings (including Extraordinary ones). Although it mentions attachments, the core purpose is the announcement and details of the meeting, making AGM-R more specific than the general RPA or RNS.
2018-01-05 Polish
Zakończenie podania leku opartego na Esketaminie pierwszej grupie uczestników I fazy badania klinicznego nad lekiem opartym na Esketaminie - Content (PL)
Regulatory Filings Classification · 95% confidence The document text is very short (790 characters) and discusses an update regarding a clinical trial phase (Phase I completion for an Esketamine-based drug). It is an announcement providing an update on ongoing operations and progress, not a full financial report (like 10-K or IR), a management change (MANG), or a formal dividend notice (DIV). Since it is an operational update that doesn't fit the specific categories like LTR (Legal), CAP (Financing), or ER (Earnings), it falls best under the general regulatory announcement category, RNS, as it is a material, non-financial operational update.
2018-01-05 Polish
Rezygnacja Członka Rady Nadzorczej Spółki - Content (PL)
Board/Management Information Classification · 98% confidence The document text is very short (313 characters) and announces a change in senior personnel: the resignation of the Chairman of the Supervisory Board (Przewodniczący Rady Nadzorczej). This directly corresponds to the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2018-01-03 Polish
Żądanie zwołania NWZ
AGM Information Classification · 95% confidence The document text is a formal request ('żądanie zwołania') by a shareholder (Apollo Capital LLC) to convene an Extraordinary General Meeting ('Nadzwyczajne Walne Zgromadzenie' or NWZ) of GLG PHARMA S.A. The agenda items explicitly focus on appointing members to the Supervisory Board ('Rady nadzorczej'). This document is a precursor to the meeting itself, detailing the required agenda and proposed resolutions. Since the content is directly related to calling and setting the agenda for a General Meeting, it falls under the scope of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting (AGM). Although it is a request for an *Extraordinary* meeting, AGM-R is the closest fit for materials related to shareholder meetings and their proceedings, especially when the agenda involves governance changes like board appointments. It is not a final voting result (DVA) or a proxy solicitation (PSI), but the material initiating the meeting.
2017-12-28 Polish
Żądanie zwołania Nadzwyczajnego Walnego Zgromadzenia Spółki. - Content (PL)
AGM Information Classification · 93% confidence The document text is very short (497 characters) and explicitly states that the Management Board (Zarząd) received a request from a shareholder (Apollo Capital LLC) to convene an Extraordinary General Meeting (Nadzwyczajne Walne Zgromadzenie Emitenta - NWZ). Crucially, it states that the company is enclosing the request along with the proposed agenda and draft resolutions. This structure—announcing the receipt of a request for a meeting and enclosing the related documents—does not fit the definitions for AGM-R (the meeting materials themselves), DEF 14A (proxy), or DVA (voting results). It is an announcement related to corporate governance and shareholder actions, but the most fitting category for an announcement regarding the process leading up to a shareholder meeting, especially when enclosing the request, is often captured under general regulatory announcements or specific governance filings. Given the options, this is an announcement concerning shareholder rights and meeting procedures. Since it is not the final proxy statement (PSI) or the voting results (DVA), and it is an official regulatory communication, it falls best under the general 'Regulatory Filings' (RNS) as a miscellaneous official announcement, or potentially related to governance/shareholder matters. However, since it is a formal notification about a shareholder action triggering a meeting, and it is not a standard report, RNS is the safest fallback. If we strictly interpret the content as an official regulatory filing about a significant corporate event (shareholder requisition), RNS is appropriate.
2017-12-28 Polish
Notyfikacja.pdf
Director's Dealing Classification · 99% confidence The document is titled "Powiadomienie o transakcji/transakcjach*, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of transaction(s) referred to in Article 19(1) of the MAR Regulation). It details a transaction (sprzedaż/sale) involving shares by a member of the management board ("Członek zarządu"), Iwona Giedronowicz, concerning Celon Pharma S.A. Article 19 of the MAR (Market Abuse Regulation) mandates notifications for transactions conducted by persons discharging managerial responsibilities (PDMRs). This specific content—reporting personal share transactions by directors/executives—directly corresponds to the definition of Director's Dealing (DIRS). The document is short and contains the specific transaction details, not an announcement of a report.
2017-12-20 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.